CCM
INZY

CAAS Capital Management’s Inozyme Pharma INZY Stock Holding History

CAAS Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-113,091
Closed -$771K – 790
2021
Q4 		$771K Sell
113,091
-22,307
-16% -$193K 0.02% 479
2021
Q3 		$1.57M Buy
+135,398
New +$2.11M 0.03% 401
2021
Q2 		– Sell
-177,502
Closed -$3.52M – 1152
2021
Q1 		$3.52M Buy
+177,502
New +$3.92M 0.04% 441

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAAS Capital Management's INZY Position: Q1 2022 in Review

CAAS Capital Management sold out of Inozyme Pharma (INZY) in Q1 2022, closing a stake of 113,091 shares — an estimated $771K sold.

CAAS Capital Management first reported a position in INZY in Q1 2021 and held it in 3 quarters. The position peaked at $3.52M in Q1 2021. 50 funds tracked by Wall St. Rank hold INZY as of Q1 2022.

  • CAAS Capital Management reported no remaining Inozyme Pharma position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 113,091 Inozyme Pharma shares in Q1 2022, an estimated $771K.
  • CAAS Capital Management first reported a position in Inozyme Pharma in Q1 2021 and held it in 3 quarters.
  • CAAS Capital Management's Inozyme Pharma position peaked at $3.52M in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.